Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TACR2 | P21452 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545119 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31544940 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31545757 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31544853 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL9472976 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31544875 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31545471 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31545637 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31544858 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL31546072 | 1.00 | CBS (0.79) | CBSPTGS2CYP3A4ESR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4627920-A1 | BINARY INSECTICIDE COMPOSITION AND USE THEREOF | Shenyang Sinochem Agrochemicals R & D Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12426782-B2 | Systems and temporal alignment methods for evaluation of gestational age and time to delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-30 | — | — | US | claimed |
| EP-3807287-B1 | METAL COMPLEXES OF BETA-DIKETONES AND/OR POLYPHENOLS BY GREEN CHEMISTRY, PREPARATION METHOD THEREOF, SUNSCREEN THEREOF, SKIN OR HAIR TONE CONCEALER THEREOF, HAIR DYEING THEREOF AND OTHER USES THEREOF | RAMIREZ RIOS LILIANA PATRICIA (NL) | 2025-07-30 | — | — | EP | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240226517-A9 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131311-A1 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | SHANGHAI MICROPORT MEDICAL GROUP CO LTD (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4295891-A1 | DRUG-LOADED MEDICAL INSTRUMENT AND PREPARATION METHOD THEREFOR | Shanghai MicroPort Medical (Group) Co., Ltd. (CN) | 2023-12-27 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2005122670-A2 | BIOMONITORED SYNTHESIS ROUTE FOR LARGE SCALE PREPARATION OF CARDOL (BILOBOL) AND 11Δ-CARDOL | KARDOL INDÚSTRIA QUÍMICA LTDA. (BR) | 2005-12-29 | — | — | WO | claimed |
| WO-2005082434-A2 | BIOCOMPATIBLE COATING, METHOD, AND USE OF MEDICAL SURFACES | HEMOTEQ GMBH (DE) | 2005-09-09 | — | — | WO | claimed |
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | HEMOTEQ AG (DE) | 2005-08-11 | — | — | US | claimed |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | HEMOTEQ AG (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2005032611-A2 | BIOCOMPATIBLE, BIOSTABLE COATING OF MEDICAL SURFACES | HEMOTEQ GMBH (DE) | 2005-04-14 | — | — | WO | claimed |
| US-20050060028-A1 | Blood biocompatible layer and adjacent layer containing antiproliferative, antiinflammatory and/or antithrombotic active agent covalently and/or adhesively bound | HEMOTEQ AG (DE) | 2005-03-17 | — | — | US | claimed |
| EP-1501565-A1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | Hemoteq GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| CN-1568166-A | Coated stent for preventing restenosis | HEMOTEQ GMBH (DE) | 2005-01-19 | — | — | CN | claimed |
| CN-1552686-A | Artificial compounds of 2-hydroxydiphenylketone and 4-hydroxytetraphenyl ketone and their derivatives as antiseptic bactericide | 国家农产品保鲜工程技术研究中心（天 | 2004-12-08 | — | — | CN | claimed |
| WO-2003094990-A1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2003-11-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CBS 1497/4885PTGS2 1452/4885CYP3A4 3571/4885 |
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | FUT5, CSGALNACT1, FUT6 | CBS 2375/4885PTGS2 389/4885CYP3A4 4298/4885 |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | MSR1, CD44, PIGS | CBS 628/4885PTGS2 328/4885CYP3A4 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.